Diligence memo · auto-generated · as of July 2, 2026
Pathovax Llc
Pathovax Llc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pathovax Llc operates in Biotechnology, based in BALTIMORE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pathovax Llc has raised $2.8M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.8M on 2018-05-10.
Most recent recorded round closed around 2018-05-10.
Valuation (modeled)modeled
Provath models Pathovax Llc at approximately $122M (range $2.0M–$958M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.72× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 8.1 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 33% of Biotechnology peers (4293 compared).
Modeled value ranks above 63% of those peers.
Closest niche peers: Mimedx Group, Inc., Kenjockety Biotechnology, LLC, Helocyte, Inc., CytoDel, INC., Finch Therapeutics, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.